FN-1501
CAS No. 1429515-59-2
FN-1501 ( —— )
Catalog No. M23592 CAS No. 1429515-59-2
FN-1501 is a potent FLT3 and CDK inhibitor (IC50s: 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively).
Purity : >98% (HPLC)
Size | Price / USD | Stock | Quantity |
5MG | 177 | In Stock |
|
10MG | 335 | In Stock |
|
25MG | 566 | In Stock |
|
50MG | 806 | In Stock |
|
100MG | 1098 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameFN-1501
-
NoteResearch use only, not for human use.
-
Brief DescriptionFN-1501 is a potent FLT3 and CDK inhibitor (IC50s: 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively).
-
DescriptionFN-1501 is a potent FLT3 and CDK inhibitor (IC50s: 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively). FN-1501 also has anticancer activity.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCdk4/cyclin D1;CDK6/cyclinD1;cdk2/cyclin A;FLT3
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1429515-59-2
-
Formula Weight431.5
-
Molecular FormulaC22H25N9O
-
Purity>98% (HPLC)
-
SolubilityDMSO: 45 mg/mL (104.29 mM);
-
SMILESO=C(C1=NNC=C1NC2=NC=NC3=C2C=CN3)NC4=CC=C(CN5CCN(C)CC5)C=C4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
PHA-848125
A potent, selective, brain penetrant and orally available dual CDK and TRK inhibitor with IC50 of 45 and 53 nM for CDK2/cyclin A and TrkA, respectively; shows cross-reactivity with other CDKs (CDK1/4/5/7), TrkB/C, Kit, Abl and PDGFR (IC50s<1 uM).
-
Alsteropaullone
Alsteropaullone (9-Nitropaullone, NSC 705701) is a derivative of kenpaullone, ATP-competitive inhibitor of CDKs and GSK3β, inhibits Cdk1/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E and Cdk5/p25 with IC50 of 35, 15, 200 and 40 nM.
-
Trilaciclib hydrochl...
Trilaciclib hydrochloride is an inhibitor of CDK4/6 (IC50s: 1 nM and 4 nM for CDK4 and CDK6).Incubation with Trilaciclib hydrochloride (G1T28) for 24 hours can induce a strong G1 cell cycle arrest (time=0). Cells have re-entered the cell cycle and demonstrate cell-cycle kinetics similar to untreated control cells By 16 hours after Trilaciclib hydrochloride washout.